Experience

Stibbe advises Mylan

Stibbe advises Mylan

21.07.2016 EU law

Stibbe advises global pharmaceutical company Mylan on the merger control aspects of its USD 7.2 billion acquisition of Swedish drugmaker Meda.

The combination of Mylan and Meda will create a diversified global pharmaceutical leader with an expansive portfolio of branded and generic medicines and a strong and growing portfolio of over-the-counter (OTC) products.

Team

Related experience

Our website uses cookies: third party analytics cookies to best adapt our website to your needs & cookies to enable social media functionalities. For more information on the use of cookies, please check our Privacy and Cookie Policy. Please note that you can change your cookie opt-ins at any time via your browser settings.

Privacy and Cookie Policy